ARTYX is a Pharmaceutical Company founded by Martin K. Lotz, M.D. and Waldemar Lernhardt, Ph.D. The Company has operated in virtual mode by relying on the core competencies of the founders for the elucidation of mechanisms of osteoarthritis pathogenesis and pre-clinical and clinical development, respectively. ARTYX benefits from contractual arrangements with respected providers of drug development services to carry out pre-clinical and clinical development work. The Company has completed clinical safety and initial efficacy testing for the first product ART144 for the treatment of joint pain associated with Osteoarthritis.